Background. E. coli are facultative anaerobic, Gram-negative bacilli that will ferment lactose to produce hydrogen sulfide. Up to 10% of isolates have historically been reported to be slow or non-lactose fermenting, though clinical differences are unknown. The aim of our study was to determine whether differences exist between non-lactose (NLFEC) and lactose fermenting E. coli (LFEC) in regards to epidemiology, pathogenicity, clinical manifestations, and antibiotic resistance.
Methods. Retrospective chart review from January 2013 to April 2016 of 150 NLFEC isolates age matched to 150 LFEC isolates from adult patients admitted to Albert Einstein Medical Center in Philadelphia PA. Mann-Whitney U analysis of data was done utilizing SPSS Statistics 24.0 (IBM Corporation)
Only the 1st isolate from an admission was included unless the same isolate was found in different cultures drawn at same time. A recurrent isolate from a patient would only be considered if separated by 3 months. Urine cultures with multiple different organisms, cultures with multiple species of E. coli, or multiple cultures w/ E. coli with variable fermentation of lactose were excluded.
Results. There were no epidemiological risk factors for isolation of NLFEC from patients. Diabetic patients and patients with CKD had more NLFEC isolates, though the difference was not statistically significant NLFEC isolates were more likely to be found in patients admitted from the community (97% vs 73% P = 0.03) rather than hospital acquired (3% vs 27% P = 0.009). There was no difference in rates of colonization (36% vs 46% P = 0.14) and pathogenicity (64% vs 54% P = 0.256), nor site of infection.
NLFEC demonstrated a trend to statistical significance to be less resistant to later generation Cephalosporin. They were less likely to be resistant to Cefepime (1% vs 8% P = 0.003) and be flagged as an ESBL isolate.
Conclusion. Non-Lactose Fermenting E. coli are more likely to be isolated from patients in the community, have no difference in predilection for nor site of infection, and are less likely to be resistant to later generation Cephalosporins Disclosures. All authors: No reported disclosures. Background. Antimicrobial resistance is a threat to public health. As carbapenem-resistant Enterobacteriaceae, multidrug-resistant Pseudomonas aeruginosa, and multidrug-resistant Acinetobacter baumannii have increased in prevalence, interest has increased in using colistin as a therapeutic option. However, testing for colistin susceptibility is problematic for most clinical microbiology laboratories. Also, there is a paucity of surveillance data on the prevalence of colistin resistance in the United States. MicroScan® Gram-negative panels include a colistin well (4 μg/mL) to aid in the identification of bacteria, but it is not known whether this well can be used to assess the prevalence of colistin resistance.
Colistin Susceptibility Testing Using the MicroScan® Colistin Well
Methods. All Escherichia coli, Klebsiella pneumoniae, K. oxytoca, Enterobacter cloacae, E. aerogenes, P. aeruginosa, or A. baumannii identified at the Emory University clinical microbiology laboratory between January 1, 2016 and December 31, 2016 were included in the study. Routine bacterial identification and antimicrobial susceptibility testing were performed using the MicroScan WalkAway 96 plus® and the Neg Breakpoint Combo Panel Type 41 or 44 (transition from 41 to 44 was made in March 2016). When these isolates were susceptible to three or fewer charted drugs, or upon provider request, a colistin ETEST® was performed.
Results. There were 288 out of 9296 isolates (3.1%) that had growth in the colistin MicroScan® well, suggesting colistin resistance. This included 79 E. coli (1.5%), 90 Klebsiella spp. (4.2%), 91 Enterobacter spp. (15.1%), 24 P. aeruginosa (1.9%), and 4 A. baumannii (3.7%). ETEST® was performed on 40 of the 288 isolates (13.9%). The MicroScan® colistin well result was confirmed (defined as an ETEST® MIC>2) in 27 out of 40 cases (67.5%).
Conclusion. Resistance to colistin, at this single academic medical center, may be higher than was previously appreciated. This is a concerning finding. Further investigation is needed to determine whether the MicroScan® colistin well can be used as a reliable surrogate for detecting colistin resistance because in this study there was a low rate of categorical agreement between the MicroScan® colistin well and ETEST®. A future study is planned comparing these two testing methodologies with reference broth microdilution.
Disclosures. All authors: No reported disclosures. Staphylococcus aureus is the leading cause of MSI and readily grows in culture; however, receipt of antibiotics prior to culture and the frequency of fastidious organisms in young children (e.g., Kingella kingae) often leads to negative cultures and broad treatment regimens. Thus, there is a need for improved rapid diagnostics in children with MSI. In this study, we compared the detection of MSI pathogens by culture and by target-enriched multiplex PCR (TEM-PCR™) in children with MSI.
Performance of TEM-PCR vs. Culture for Bacterial Identification in Pediatric Musculoskeletal Infections
Methods. Synovial fluid and bone samples were collected from patients with MSI (n = 25, 0.5-18 years). Bacterial cultures and antibiotic susceptibility testing (AST) was performed by the Vanderbilt University Medical Center clinical laboratory. Additionally, samples were evaluated by TEM-PCR for detection of S. aureus [including methicillin and clindamycin resistance genes and the Panton-Valentine leukocidin (PVL) locus], K. kingae, Haemophilus influenzae, Streptococcus pyogenes, and Streptococcus pneumoniae.
Results. TEM-PCR detected a pathogen in 20/25 subjects (80%), compared with 17/25 (68%) by culture. S. aureus was identified in 18 subjects, one of which was identified by TEM-PCR and not by culture. TEM-PCR also identified 2 subjects with K. kingae infection; neither was identified by culture. TEM-PCR detection of methicillin resistance and clindamycin resistance was 100% concordant with AST in the clinical laboratory. Genes encoding PVL were identified in 8/18 (44%) S. aureus samples. No bacterial co-detections were identified, and no other pathogens were identified by TEM-PCR or culture. Finally, there were no subjects with positive bacterial cultures and negative TEM-PCR results.
Conclusion. Rapid diagnostic assays, such as TEM-PCR, may be useful adjuncts to conventional, culture-based testing for children with MSI. Advantages include rapid identification of pathogen and early detection of antibiotic resistance genes. In a single multiplex assay, TEM-PCR provided reliable identification of MSI pathogens, with the potential for informing antibiotic selection early in the disease course.
